The company announced its interim results for the fiscal year ending March 2027 on 11/16, reporting revenue of ¥3.292 billion and an operating loss that widened to ¥244.1 million. After the results announcement, the share price fell from ¥625 on 11/13 to ¥498 on 11/20, including a 5.56% drop from the previous day on 11/17.
The interim results announced on 11/16 showed revenue of ¥3.292 billion, down 2.5% year on year, and an operating loss that widened to ¥244.1 million. The ordinary loss was ¥229.1 million, while the interim net loss attributable to owners of the parent also worsened to ¥186.8 million. The risk management business swung to an operating loss.
Following the results announcement, the share price fell 5.56% from the previous day on 11/17 and declined to ¥498 on 11/20. As a result, the recent share-price trend remains in a downward phase following the interim results.
The factors cited as points to monitor for future performance include the accumulation of drug-discovery projects and growth in the DX business, while risk factors identified include sales fluctuations resulting from cancellations and variations in the timing of revenue recognition for government-agency projects. As of now, publicly available information does not include any specific numerical outlook for future performance.